Document is current
Any future updates will be listed below
-
Authors
Al-Khalidi, Rasha
Panicucci, Chiara
Cox, Paul
Chira, Natalia
Róg, Justyna
Young, Christopher N. J.
McGeehan, Rhiannon E.
Ambati, Kameshwari
Ambati, Jayakrishna
Zabłocki, Krzysztof
Gazzerro, Elisabetta
Arkle, Stephen
Bruno, Claudio
Górecki, Dariusz C. http://orcid.org/0000-0003-3584-1654
-
Funding
Funding for this research was provided by:
Higher Committee for Education Development in Iraq (NA)
National Science Centre, Poland (DEC-2013/11/B/NZ3/01573)
European Cooperation in Science and Technology (BM1406)
National Institutes of Health (DP1GM114862, R01EY022238, R01EY024068)
John Templeton Foundation
DuPont Guerry, III Professorship
- License Information
-
More Information
Article History
Received: 26 March 2018
Accepted: 28 March 2018
First Online: 11 April 2018
Ethics approval
: All animal experiments were performed in accordance with the Principles of Laboratory Animal Care (NIH publication No. 86–23, revised 1985) and approvals of the Institutional Ethical Review Board and the Home Office UK (70/7479).
: Not Applicable.
: J.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems and Inflammasome Therapeutics and has been a consultant for Allergan, Biogen, Olix Pharmaceuticals, and Saksin LifeSciences in a capacity unrelated to this work. J.A. and K.A. are named as inventors on patent applications on macular degeneration filed by the University of Kentucky or the University of Virginia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
